Effect of Twice Daily Administration of GH-releasing Peptide-2 for 10 Days on Growth Performance, Plasma GH Responses and Insulin-like Growth Factor-1 Concentrations in Swine

  • Nou, V. (Laboratory of Animal Production, Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine) ;
  • Inoue, H. (Laboratory of Animal Production, Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine) ;
  • Lee, H.G. (Laboratory of Animal Production, Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine) ;
  • Matsunaga, N. (Laboratory of Animal Production, Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine) ;
  • Kuwayama, H. (Laboratory of Animal Production, Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine) ;
  • Hidari, H. (Laboratory of Animal Production, Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine)
  • Received : 2002.09.26
  • Accepted : 2003.02.28
  • Published : 2003.08.01


An increase in frequency of administration of exogenous growth hormone (GH) or GH-releasing hormone was reported to be a model to increase blood circulating insulin-like growth factor-1 (IGF-1) and to improve growth performance in animals. We have investigated the effect of twice daily administration of GH-releasing peptide-2 (GHRP-2) on growth performance, GH responsiveness and plasma insulin-like growth factor IGF-1 in swine. We administered to eight swine, 3 control and 5 treatment, a twice daily s.c. injections of GHRP-2 ($30{\mu}g/kg\;BW$) for a period of 10 days. Every day blood samples immediately taken before injections of GHRP-2 or saline, at 08:00 h and 16:00 h, were measured for IGF-1 concentrations. Blood samples for GH assay were collected every 20 min on days 1, 6 and 10, from 1 hour before and 3 h after GHRP-2 or saline injections at 08:00 h. GH peak concentrations and GH area under curve (GH AUC) on day 1, 6 and 10 in treatment group of swine were higher than those in control swine (p<0.05). Twice daily administration of GHRP-2 caused a significantly attenuation (p<0.05) of GH peak concentrations ($80.25{\pm}13.87$, $39.73{\pm}5.72$ and $27.57{\pm}6.06ng/ml$ for day 1, 6 and 10, respectively) and GH AUCs ($3,536.15{\pm}738.35$, $1,310.31{\pm}203.55$ and $934.37{\pm}208.99ng/ml$ for day 1, 6 and 10, respectively). However, there was no significant difference in GH peak concentration and GH AUC between day 6 and 10. Plasma IGF-1 concentration levels were higher in treatment than control group of swine (p<0.05) after 3 days of the treatment, and the levels reached a plateau from day 3 to 10 of experiment. Growth performance did not alter by GHRP-2 administration, even though a numerical increase of body weight gain and feed efficiency was observed. These results indicate that twice daily administration of GHRP-2 for 10 days in swine did not significantly influence on growth performance, caused an overall attenuation of GH response, and that elevation of plasma GH concentrations caused by GHRP-2 administration increased plasma IGF-1 concentrations, even though an attenuation of GH response was observed.


GH;GHRP-2;IGF-1;Growth Performance;Swine


Supported by : Grants-in-aid to H.H.


  1. Bowers, C. Y. and R. Granda-Ayala. 2001. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormonereleasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine 14:79-86.
  2. Daughaday, W. H., K. Hall and M. S. Raben. 1972. Somatomedin: a proposed designation for the 'sulphation factor'. Nature 235:107-109.
  3. Dubreuil, P., D. Petitclerc, G. Pelletier, P. Gaudreau, C. Farmer, T. F. Mowles and P. Brazeau. 1990. Effect of dose and frequency of administration of a potent analog of human growth hormone-releasing factor on hormone secretion and growth in pigs. J. Anim. Sci. 68:1254-1268.
  4. Jansson, J. O., K. Albertsson-Wikland, S. Eden, K. G. Thorngren and O. Isaksson. 1982. Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol. Scand. 114: 261-265.
  5. Min, S. H., D. D. S. Mackenzie, B. H. Breier, S. N. Mccutcheon and P. D. Gluckman. 1996. Responses of young energyrestricted sheep to chronically administered insulin-like growth factor-I (IGF-1): evidence that IGF-1 suppresses the hepatic growth hormone receptor. Endocrinology 137:1129-1137.
  6. Thomas, G. B., P. A. Bennett, D. F. Carmignac and I. C. A. F. Robinson. 2000. Glucocorticoid regulation of growth hormone (GH) secretagogue-induced GH responses and GH secretagogue receptor expression in the rat. GH & IGF Res. 10:45-52.
  7. Vance, M. L., D. L. Kaiser, P. M. Martha, R. Furlanetto, J. Rivier and W. Vale. 1989. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. J. Clin. Endocrinol. Metab. 68:22-28.
  8. Wu, D., C. Chen, K. Katoh, J. Zeng and I. J. Clarke. 1994. The effect of GH-releasing peptide-2 (GHRP-2 or GHRP-2) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist. J. Endocrinol. 140:R9-R13.
  9. Gondo, R. G., M. H. Aguiar-Oliveira, C. Y. Hayashida, S. P. Toledo, N. Abelin, M. A. Levine, C. Y. Bowers, A. H. Souza, R. M. Pereira, N. L. Santos and R. Salvatori. 2001. Growth hormone-releasing peptide-2 stimulates GH secretion in GHdeficient patients with mutated GH-releasing hormone receptor. J. Clin. Endocrinol. Metab. 86:3279-3283.
  10. Kensinger, R. S., L. M. McMunn, R. K. Stover, B. R. Schricker, M. L. Maccecchini, H. W. Harpster and J. F. Kavanaugh. 1987. Plasma somatotropin response to exogenous growth hormone releasing factor in lambs. J. Anim. Sci. 64:1002-1009.
  11. Roh, S. G., M. L. He, N. Matsunaga, S. Hidaka and H. Hidari. 1997. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. J. Anim. Sci. 75:2744-2748.
  12. Daughaday, W. H., I. K. Mariz and S. L. Blethen. 1980. Inhibition of assess of bound somatomedin to membrane receptor and immunobinding sites: A comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanolextracted serum. J. Clin. Endocrinol. Metab. 51:781-788.
  13. Sillence, M. N. and T. D. Etherton. 1987. Determination of the temporal relationship between porcine growth hormone, serum IGF-1 and cortisol concentrations in pigs. J. Anim. Sci. 64:1019-1023.
  14. Phung, L. T., N. Matsunaga, S. Hidaka, H. Kuwayama and H. Hidari. 2001. Growth hormone-releasing peptide-2 (GHRP-2) acts synergistically with growth hormone-releasing hormone (GHRH) to release growth hormone (GH) in swine. Anim. Sci. J. (Jpn), 72:315-321.
  15. Raun, K., B. S. Hansen, N. L. Johansen, H. Thogersen, K. Madsen, M. Andersen and P. H. Andersen.1998. Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. 139:552-561.
  16. Shimon, I., X. Yan and S. Melmed. Human fetal pituitary express functional growth hormone-releasing peptide receptors. 1998. J. Clin. Endocrinol. Metab. 83:174-178.
  17. Bick, T., Z. Hochberg, T. Amit, O. G. Isaksson and J. O. Jansson. 1992. Roles of pulsatility and continuity of growth hormone (GH) administration in the regulation of hepatic GH-receptors, and circulating GH-binding protein and insulin-like growth factor-I. Endocrinology 131:423-429.
  18. Etherton, T. D., J. P. Wiggins, C. M. Evock, C. S. Chung, J. F. Rebhun, P. E. Walton and N. C. Steele. 1987. Stimulation of pig growth performance by porcine growth hormone: determination of the dose-response relationship. J. Anim. Sci. 64:433-443.
  19. Hashimizume, T., K. Sasaki, S. Kobayashi and Y. Nitta. 1998. Intrahypothalamic perfusion of GHRP-2 stimulates growth hormone release in goats. Endocrine J. 45:53-59.
  20. Vanderkool, W. K., M. J. Vandehaar, B. K. Sharma, M. Binelli, H. A. Tucker, R. M. Akers and W. M. Moseley. 1995. Comparison of growth hormone-releasing factor and somatotropin: the somatotropic axis in lactating primiparous cows. J. Dairy Sci. 78:2140-2149.
  21. Brameld, J. M., J. L. Atkinson, J. C. Saunders, J. M. Pell, P. J. Buttery and R. S. Gimour. 1996. Effects of growth hormone administration and dietary protein intake on insulin-like growth factor-I and growth hormone receptor mRNA expression in porcine liver, skeletal muscle and adipose tissue. J. Anim. Sci. 74:1832-1841.
  22. Phung, L. T., H. Inoue, V. Nou, H. G. Lee, R. A. Vega, N. Matsunaga, S. Hidaka, H. Kuwayama and H. Hidari. 2000. The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Domest. Anim. Endocrinol. 18:279-291.
  23. Ling, S. C, F. Esch, P. Bohlen, P. Brazeau, W. B. Wehrenberg and M. G. Rosenfeld. 1993. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 364:208-213.
  24. Ghigo, E., L. Gianotti, E. Arvat, J. Ramunni, M. R. Valetto, F. Broglio, M. Rolla, F. Cavagnini and E. E. Muller. 1999. Effects of rhIGF-1 administration on GH secretion both spontaneous and stimulated by GHRH or hexarelin, a peptidyl GH secretagogue in humans. J. Clin. Endocrinol. Metab. 84:285-290.
  25. Nijland, E. A., C. J. Strasburger, C. P. Snijders, P. S. Van der wal and E. A. Van der veen. 1998. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulinlike growth factor-I secretion in healthy young men. Eur. J. Endocrinol. 139:395-401.
  26. Jorgensen, J. O., N. Moller, T. Lauritzen and J. S. Christiansen. 1990. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J. Clin. Endocrinol. Metab. 70:1616-1623.
  27. Korytko, A. I. and L. Cuttler. 2001. Regulation of GHRH receptor gene expression in the neonatal and adult rat pituitary. GH & IGF Res. 11:282-288.
  28. Kovacs, M., R. D. Kineman, A. V. Schally, B. Flerko and L. A. Frohman. 2000. Increase in mRNA concentrations of pituitary receptors for growth hormone-releasing factor and growth hormone secretagogues after neonatal monosodium glutamate treatment. J. Neuroendocrinol. 12:335-341.
  29. Dubreuil, P., D. Peticlerc, P. Gaudreau, P. Brazeau and G. Pelletier. 1991. Effect of growth hormone-releasing factor infusion on somatotropin, prolactin, thyroxine, insulin, insulin-like growth factor-I and blood metabolites in control and somatostatinimmunized growing pigs. Domest. Anim. Endocrinol 8:307-321.
  30. Sawada, H., H. Sugihara, H. Onose, S. Minami, T. Shibasaki and I. Wakabayashi. 1994. Effect of D-Ala-D-$\beta$Nal-Ala-Trp-D-Phe-Lys-$NH_2$ (GHRP-2) on GH secretion urethan-unesthetised rats. Regul. Pepts. 53:195-210.
  31. Jorgensen, J. O., W. F. Blum, N. Moller, M. B. Ranke and J. S. Christiansen. 1991. Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GHdeficient patients. J. Clin. Endocrinol. Metab. 72: 582-587.
  32. Lee, H. G., R. A. Vega, L. T. Phung, N. Matsunaga, H. Kuwayama and H. Hidari. 2000. The effect of growth-releasing peptide-2 (GHRP-2) administration on plasma insulin-like growth factor (IGF)-1 and IGF-binding proteins in Holstein steers on different planes of nutrition. Domest. Anim. Endocrinol. 18:293-308.
  33. Coleman, M. E., L. Russell and T. D. Etherton. 1994. Porcine somatotropin (pST) increases IGF-1 mRNA abundance in liver and subcutaneous (s.c.) adipose tissue but not in skeletal muscle of growing pigs. J. Anim. Sci. 72:918-924.
  34. Nakagawa, T., K. Ukai, T. Ohyama, M. Koida and H. Okamura. 1996. Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats. Life Sci. 59:705-712.
  35. Shah, N., W. S. Evans, C. Y. Bowers and J. D. Veldhuis. 1999. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in Women by continuous 24-hour GHreleasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms. J. Clin. Endocrinol. Metab. 84:2140-2150.
  36. Roh, S. G., N. Matsunaga, S. Hidaka and H. Hidari. 1996. Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves. Endocrine J. 43:291-298.